Manufacturing of a Dissolving Microneedle Patch to Administer Rotavirus Vaccine

Closed Special Notice Posted

Solicitation number
CDC-75D301-Presolicitation-MfgDMNPatch
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
Atlanta, Georgia 30318, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The Centers for Disease Control and Prevention (CDC) National Center for Immunizations and Respiratory Diseases has issued a Notice of Intent to Award a sole source contract to Micron Biomedical Incorporated for the manufacturing of dissolving microneedle patches designed to administer rotavirus vaccine. This special notice, posted on March 24, 2026, indicates the CDC's intention to proceed with a non-competitive award based on the determination that only one responsible source can satisfy the agency's requirements. The contract is valued under FAR 13.106-1(b)(1)(i) and 10 U.S.C. 2304(c)(1) authorities, which permit sole source procurement when unique capabilities are required. The anticipated award date is on or before April 24, 2026, with a contract period extending from April 15, 2026 through April 14, 2028. The applicable NAICS classification is 541715, covering Research and Development in the Physical, Engineering, and Life Sciences.

The primary objective of this contract is to manufacture microneedle patch delivery systems for live attenuated rotavirus vaccine intended for use in a planned clinical trial. Interested sources must submit a capability statement not exceeding two pages (8.5 x 11 inches with minimum 10-point font) by the April 8, 2026 due date, including management and technical data with convincing evidence of capability to provide the required services and warranties. While this notice is not a request for competitive proposals and no formal solicitation document exists, all capability statements received by the deadline will be considered by the government. There are no specific set-asides or eligibility restrictions mentioned, though contractors must demonstrate sufficient technical and management capability relevant to microneedle patch manufacturing and vaccine delivery systems. The government retains sole discretion to determine whether to compete this requirement based on the responses received.

Notice text

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Centers for Disease Control and Prevention (CDC) National Center for Immunizations and Respiratory Diseases (NCIRD) intends to award a Firm Fixed Price Contract to Micron Biomedical Incorporated 311 FERST Drive NW STE L1309 Atlanta, Georgia 30318-5602. Under the authority of FAR 13.106-1(b)(1)(i) and 10U.S.C. 2304(c)(1), only one responsible source and no other supplies or services will satisfy agency requirements. The requirement is to manufacture microneedle (MN) patch to deliver live attenuated rotavirus vaccine for use in a planned clinical trial in the future.

The Period of Performance is from 4/15/2026 thru 04/14/2028.

The anticipated award date of this action is on or before April 24, 2026. The applicable NAICS code is 541715: Research and Development In The Physical, Engineering And Life Sciences (Except Nanotechnology And Biotechnology). This notice of intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the warranties and proof as being capable of providing the requesting services. Capability Statements shall not exceed 2 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. Capability Statements are due by 10:00 AM Eastern Standard Time (EST), April 8, 2026. Capability Statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to Tim Williams email address at: TPW8@cdc.gov NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.

Similar open opportunities

Opportunity Agency Set-aside Responses due
1-Year OEM Service Contract - (2) Revvity Celigo S Imaging Instruments (VRC) Bethesda, Maryland 20892, United States · NAICS 811210 National Institute of Allergy and Infectious Diseases No set-aside
Notice of Intent to Sole Source a Thermo Orbitrap Fusion Lumos and Thermo RSLCnano UPLC Maintenance Agreement Georgia 30329, United States · NAICS 811210 CDC Office of Acquisition Services No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors